OR WAIT null SECS
July 19, 2024
With this acquisition, AstraZeneca gets a Phase III therapeutic peptide candidate that adds to the company's rare disease pipeline.
July 18, 2024
Merck gains a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration through its acquisition of EyeBio.
July 17, 2024
Johnson & Johnson gains NM26, a Phase II-ready bispecific antibody in development for atopic dermatitis, boosting its immune-mediated and inflammatory disease portfolio.
July 15, 2024
The acquisition provides Lantheus with worldwide exclusive rights to ß amyloid PET imaging agent, NAV-4694, for its Alzheimer’s disease diagnostic and treatment portfolio.
July 12, 2024
Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.
July 08, 2024
Roche voluntarily recalled Susvimo’s ocular implant, insertion tool, and initial fill kit when test results did not satisfy company standards.
Other indications for which the Sanofi treatment has been approved include atopic dermatitis, asthma, and chronic rhinosinusitis.
July 04, 2024
The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.
July 02, 2024
The company is referring to its search for innovative approaches as crowdsourcing and will award at least one cash prize.
GSK’s application for using Jemperli (dostarlimab) plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer has been accepted by the EMA.